Upadacitinib

Medication

About

Thing
Upadacitinib, sold under brand name Rinvoq, is a Janus kinase inhibitor medication for the treatment of moderately to severely active rheumatoid arthritis in adults where methotrexate did not work well or could not be tolerated.
Upadacitinib
Definition
Upadacitinib, sold under brand name Rinvoq, is a Janus kinase inhibitor medication for the treatment of moderately to severely active rheumatoid arthritis in adults where methotrexate did not work well or could not be tolerated.
Upadacitinib
Upadacitinib
Upadacitinib, sold under brand name Rinvoq, is a Janus kinase inhibitor medication for the treatment of moderately to severely active rheumatoid arthritis in adults where methotrexate did not work well or could not be tolerated.

Mentions

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-PsA 1 clinical trial. In this study, both doses of RINVOQ (upadacitinib; 15 mg and 30 mg, once daily) met the primary endpoint of ACR20 response at week 12 versus placebo in adult patients with active psoriatic arthritis who have responded inadequately or are intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs). RINVOQ also demonstrated significant improvements in signs and symptoms of the disease across a variety of endpoints compared to placebo. RINVOQ, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as a once-daily therapy in psoriatic arthritis and multiple immune-mediated inflammatory diseases.

See also: